While some biopharma companies are slashing headcounts, AstraZeneca is adding 500 scientific and high-tech jobs with a significant expansion of its R&D operations in Toronto.
Aptinyx’s NYX-458 fell short of the primary endpoint in a Phase II trial of patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
The decision comes nearly a month after it scrapped a late-stage study of Keytruda in some prostate cancer patients and puts the drugmaker further behind in its quest to develop a treatment for advanced forms of the most common cancer type in the United States.
The frontrunners in a crowded race to develop the first respiratory syncytial virus vaccine – Pfizer Inc and GSK – will face scrutiny from a panel of experts to the U.S. Food and Drug Administration this week.
The FDA’s controversial neuroscience head is stepping down from his post to “explore other opportunities,” according to an internal FDA e-mail.
The U.S. Supreme Court on Monday declined to hear a challenge to Los Angeles County’s ban on sales of flavored tobacco products brought by R.J. Reynolds Tobacco Company, which had argued that only the federal government – not state or local governments – has the legal authority to regulate tobacco products.
ALS is the 5,000-piece jigsaw puzzle of the therapeutic world. As the regulatory edges come together, new research pieces are also connecting.
2022 was a big year for uniQure with the U.S. and European approval of world’s first gene therapy for hemophilia B. In its 2022 financial report Monday, the Lexington, Mass. and Amsterdam-based company provided updates on the progress of its Huntington’s disease and ALS programs.
ReutersLucira Health said on Monday the U.S. Food and Drug Administration (FDA) had granted emergency use authorization for its combination diagnostic test for COVID-19 and the flu, making it the first to be available over-the-counter.
Following its failed deal with Merck last year, Seagen has a new suitor. The Seattle-based company is in talks with Pfizer over a potential acquisition, The Wall Street Journal reported Sunday evening, citing people familiar with the matter.
